for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-AstraZeneca Says Tezepelumab Phase III Trial Met Primary Endpoint

Nov 10 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA PLC - TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINT

* ASTRAZENECA - TRIAL ALSO MET PRIMARY ENDPOINT IN PATIENTS WITH LOW LEVELS OF EOSINOPHILS

* ASTRAZENECA - POSITIVE RESULTS FROM NAVIGATOR PHASE III TRIAL FOR POTENTIAL NEW MEDICINE TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up